9 active not recruiting, 6 terminated, 5 completed, 3 withdrawn. 25 Phase 1, 11 Phase 2, 1 Phase 3.
Follow AP 1903 reagent: new trials by email Literature Review of AP 1903 reagent trials Research Report on AP 1903 reagent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid - Breast Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2026-10-01 | 2026-08-19 |
| Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine - Gastric Cancer, Metastatic | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 10 | 2026-08-11 | 2026-10-08 |
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma Cyclophosphamide, Fludarabine, EB-CAR30-NK - B2 Thymoma, Thymic Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-05-20 |
| Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) Fludarabine Phosphate, Cyclophosphamide, Cetuximab - Colorectal Cancer, Minimal Residual Disease | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2024-12-02 | 2026-08-04 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Rimiducid - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2019-06-13 | 2021-09-09 |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma iC9-CAR19 T cells, Bendamustine, Fludarabine - Lymphoma, Lymphoma, B-Cell | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2019-03-12 | 2026-07-31 |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Terminated | Bellicum Pharmaceuticals | 1 | 2018-12-27 | 2023-09-29 |
| Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant BPX-501 T cells, rimiducid - Hematologic Malignancy | Phase 1 | Active not recruiting | Bellicum Pharmaceuticals | 15 | 2018-02-01 | 2022-07-12 |
| Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies Fludarabine, Cyclophosphamide, Mesna - B-Lymphoid Malignancies, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 49 | 2017-06-21 | 2024-03-25 |
| Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma BPX-701, Rimiducid - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 4 | 2017-04-14 | 2023-10-05 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Rimiducid, rivogenlecleucel - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2017-01-01 | 2023-09-26 |
| Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors BPX-601, Rimiducid - Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Terminated | Regeneron Pharmaceuticals | 52 | 2016-11-30 | 2026-02-23 |
| Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies BPX-501, AP1903 - Hematologic Malignancies | Phase 1 | Withdrawn | Bellicum Pharmaceuticals | 2016-07-01 | 2020-10-05 | |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant BPX-501, Rimiducid - Leukemia, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Bellicum Pharmaceuticals | 10 | 2016-07-01 | 2022-07-12 |
| T-Cell Therapy for Advanced Breast Cancer Cyclophosphamide, Mesothelin-targeted T cells, AP1903 - Breast Cancer, Metastatic HER2-negative Breast | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 186 | 2016-06-01 | 2026-07-16 |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT rivogenlecleucel, Rimiducid - Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Bellicum Pharmaceuticals | 2016-05-01 | 2020-10-05 | |
| Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Active not recruiting | Bellicum Pharmaceuticals | 120 | 2014-04-01 | 2022-07-12 |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2014-04-01 | 2023-09-29 |
Showing 20 of 29. Sign in to see all of them.
Myelodysplastic Syndromes (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Leukemia (9) · Leukemia, Myeloid, Acute (9) · Hematologic Neoplasms (7) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Multiple Myeloma (4) · Anemia, Aplastic (3) · Cytopenia (3) · Hodgkin Disease (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Primary Immunodeficiency Diseases (3)
Bellicum Pharmaceuticals (13) · M.D. Anderson Cancer Center (6) · UNC Lineberger Comprehensive Cancer Center (3) · National Cancer Institute (NCI) (2) · Baylor College of Medicine (1) · Beijing Biotech (1) · Fred Hutchinson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Regeneron Pharmaceuticals (1)
United States (24) · Italy (3) · China (1) · United Kingdom (1)
Bora Lim, MD (1) · Brian D Badgwell, MD (1) · Elizabeth Krakow (1) · Guru Sonpavde, MD (1) · Helen E Heslop, MD (1) · James N Kochenderfer, M.D. (1) · Lawrence Fong, MD (1) · Loretta Nastoupil, MD (1) · Maria Pia Morelli, MD, PhD (1) · Matthew Foster, MD (1) · Natalie Grover, MD (1) · Natalie S Grover, MD (1)
PMID 25977584, PMID 32023374, PMID 38134936, PMID 38238616, PMID 39737899
K12CA120780 (1), P30CA015704 (1)